Changes in CYP1A2 activity in humans after 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) administration using caffeine as a probe drug

Drug Metabolism and Pharmacokinetics

Volumn 27, Issue 6, 2012, Pages 605-613

  Yubero Lahoz, Samanta ^a,c   Pardo, Ricardo ^a,b   Farre, Magí ^a,b,d   Mathuna, Brian Ó ^a,c   Torrens, Marta ^a,b   Mustata, Cristina ^a,b   Perez Mañá, Clara ^a,b   Langohr, Klaus ^a,e   Carbó, Marcel lí ^a,c   de la Torre, Rafael ^a,c,f  

^a HOSPITAL DEL MAR   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c UNIVERSITAT POMPEU FABRA   (Spain)

^d Red de Trastornos Adictivos (FIS RTA RD06/0001/0026)   (Spain)

^e UNIVERSITAT POLITÈCNICA DE CATALUNYA   (Spain)

^f CIBEROBN   (Spain)

Author keywords

Caffeine; Clinical pharmacokinetics; CYP1A2; CYP2D6; Drug interactions; MDMA; Mechanism based inhibition

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; CAFFEINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2D6; PARAXANTHINE;

ADULT; ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DRUG DEPENDENCE; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; FEMALE; HUMAN; IN VIVO STUDY; MALE; SEX DIFFERENCE;

EID: 84871681998     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-12-RG-032     Document Type: Article

References (39)

1. de la Torre, R. and Farre, M.: Neurotoxicity of MDMA (ecstasy): the limitations of scaling from animals to humans. Trends Pharmacol. Sci., 25: 505-508 (2004).
2. Perfetti, X., O'Mathuna, B., Pizarro, N., Cuyas, E., Khymenets, O., Almeida, B., Pellegrini, M., Pichini, S., Lau, S. S., Monks, T. J., Farre, M., Pascual, J. A., Joglar, J. and de la Torre, R.: Neurotoxic thioether adducts of 3,4-methylenedioxymethamphetamine identified in human urine after ecstasy ingestion. Drug Metab. Dispos., 37: 1448-1455 (2009).
3. Jones, D. C., Duvauchelle, C., Ikegami, A., Olsen, C. M., Lau, S. S., de la Torre, R. and Monks, T. J.: Serotonergic neurotoxic metabolites of ecstasy identified in rat brain. J. Pharmacol. Exp. Ther., 313: 422-431 (2005).
4. +/%)-methylendioxymethamphetamine (ecstasy) is potentiated by inhibition of gamma-glutamyl transpeptidase. Chem. Res. Toxicol., 14: 863-870 (2001).
5. Maurer, H. H.: On the metabolism and the toxicological analysis of methylenedioxyphenylalkylamine designer drugs by gas chromatography-mass spectrometry. Ther. Drug Monit., 18: 465-470 (1996).
6. Maurer, H. H., Bickeboeller-Friedrich, J. and Kraemer, T.: Gas chromatographic-mass spectrometric procedures for determination of the catechol-O-methyltransferase (COMT) activity and for detection of unstable catecholic metabolites in human and rat liver preparations after COMT catalyzed in statu nascendi derivatization using S-adenosylmethionine. J. Chromatogr. B Biomed. Sci. Appl., 739: 325-335 (2000).
7. de la Torre, R., Farré, M., Roset, P. N., Pizarro, N., Abanades, S., Segura, M., Segura, J. and Camí, J.: Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. Ther. Drug Monit., 26: 137-144 (2004).
8. Hiramatsu, M., Kumagai, Y., Unger, S. E. and Cho, A. K.: Metabolism of methylenedioxymethamphetamine: formation of dihydroxymethamphetamine and a quinone identified as its glutathione adduct. J. Pharmacol. Exp. Ther., 254: 521-527 (1990).
9. Kreth, K., Kovar, K., Schwab, M. and Zanger, U. M.: Identification of the human cytochromes P450 involved in the oxidative metabolism of "Ecstasy"-related designer drugs. Biochem. Pharmacol., 59: 1563-1571 (2000).
10. Meyer, M. R., Peters, F. T. and Maurer, H. H.: The role of human hepatic cytochrome P450 isozymes in the metabolism of racemic 3,4-methylenedioxy-methamphetamine and its enantiomers. Drug Metab. Dispos., 36: 2345-2354 (2008).
11. Heydari, A., Yeo, K. R., Lennard, M. S., Ellis, S. W., Tucker, G. T. and Rostami-Hodjegan, A.: Mechanism-based inactivation of CYP2D6 by methylenedioxymethamphetamine. Drug Metab. Dispos., 32: 1213-1217 (2004).
12. O'Mathúna, B., Farre, M., Rostami-Hodjegan, A., Yang, J., Cuyas, E., Torrens, M., Pardo, R., Abanades, S., Maluf, S., Tucker, G. T. and de la Torre, R.: The consequences of 3,4-methylenedioxymethamphetamine induced CYP2D6 inhibition in humans. J. Clin. Psychopharmacol., 28: 523-529 (2008).
13. Yang, J., Jamei, M., Heydari, A., Yeo, K. R., de la Torre, R., Farre, M., Tucker, G. T. and Rostami-Hodjegan, A.: Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA. J. Psychopharmacol., 20: 842-849 (2006).
14. Delaforge, M., Jaouen, M. and Bouille, G.: Inhibitory metabolite complex formation of methylenedioxymethamphetamine with rat and human cytochrome P450. Particular involvement of CYP 2D. Environ. Toxicol. Pharmacol., 7: 153-158 (1999).
15. Farré, M., de la Torre, R., Mathúna, B. O., Roset, P. N., Peiró, A. M., Torrens, M., Ortuño, J., Pujadas, M. and Camí, J.: Repeated doses administration of MDMA in humans: pharmacological effects and pharmacokinetics. Psychopharmacology (Berl.), 173: 364-375 (2004).
16. Segura, M., Farre, M., Pichini, S., Peiro, A. M., Roset, P. N., Ramirez, A., Ortuno, J., Pacifici, R., Zuccaro, P., Segura, J. and de la Torre, R.: Contribution of cytochrome P450 2D6 to 3,4-methylenedioxymethamphetamine disposition in humans: use of paroxetine as a metabolic inhibitor probe. Clin. Pharmacokinet., 44: 649-660 (2005).
17. Antolino-Lobo, I., Meulenbelt, J., Nijmeijer, S. M., Scherpenisse, P., van den Berg, M. and van Duursen, M. B.: Differential roles of phase I and phase II enzymes in 3,4-methylendioxymethamphetamine-induced cytotoxicity. Drug Metab. Dispos., 38: 1105-1112 (2010).
18. Yubero-Lahoz, S., Pardo, R., Farre, M., O'Mahony, B., Torrens, M., Mustata, C., Perez-Mana, C., Carbo, M. and de la Torre, R.: Sex differences in 3,4-methylenedioxymethamphetamine (MDMA; ecstasy)-induced cytochrome P450 2D6 inhibition in humans. Clin. Pharmacokinet., 50: 319-329 (2011).
19. Pizarro, N., Ortuño, J., Farré, M., Hernández-López, C., Pujadas, M., Llebaria, A., Joglar, J., Roset, P. N., Mas, M., Segura, J., Camí, J. and de la Torre, R.: Determination of MDMA and its metabolites in blood and urine by gas chromatography-mass spectrometry and analysis of enantiomers by capillary electrophoresis. J. Anal. Toxicol., 26: 157-165 (2002).
20. Lampe, J. W., King, I. B., Li, S., Grate, M. T., Barale, K. V., Chen, C., Feng, Z. and Potter, J. D.: Brassica vegetables increase and apiaceous vegetables decrease cytochrome P450 1A2 activity in humans: changes in caffeine metabolite ratios in response to controlled vegetable diets. Carcinogenesis, 21: 1157-1162 (2000).
21. Miners, J. O. and Birkett, D. J.: The use of caffeine as a metabolic probe for human drug metabolizing enzymes. Gen. Pharmacol., 27: 245-249 (1996).
22. Valero, F., de la Torre, R., Boobis, A. R., Murray, S. and Segura, J.: Assay of caffeine metabolism in vitro by human liver microsomes using radio-high-performance liquid chromatography. J. Pharm. Biomed. Anal., 8: 783-787 (1990).
23. Rostami-Hodjegan, A., Nurminen, S., Jackson, P. R. and Tucker, G. T.: Caffeine urinary metabolite ratios as markers of enzyme activity: a theoretical assessment. Pharmacogenetics, 6: 121-149 (1996).
24. Torrens, M., Serrano, D., Astals, M., Perez-Dominguez, G. and Martin-Santos, R.: Diagnosing comorbid psychiatric disorders in substance abusers: validity of the Spanish versions of the Psychiatric Research Interview for Substance and Mental Disorders and the Structured Clinical Interview for DSM-IV. Am. J. Psychiatry, 161: 1231-1237 (2004).
25. Schmid, B., Bircher, J., Preisig, R. and Kupfer, A.: Polymorphic dextromethorphan metabolism: co-segregation of oxidative Odemethylation with debrisoquin hydroxylation. Clin. Pharmacol. Ther., 38: 618-624 (1985).
26. Carbó, M., Segura, J., de la Torre, R., Badenas, J. M. and Cami, J.: Effect of quinolones on caffeine disposition. Clin. Pharmacol. Ther., 45: 234-240 (1989).
27. Pizarro, N., Llebaria, A., Cano, S., Joglar, J., Farre, M., Segura, J. and de la Torre, R.: Stereochemical analysis of 3,4-methylenedi-oxymethamphetamine and its main metabolites by gas chromatography/ mass spectrometry. Rapid Commun. Mass Spectrom., 17: 330-336 (2003).
28. Carmo, H., Brulport, M., Hermes, M., Oesch, F., Silva, R., Ferreira, L. M., Branco, P. S., Boer, D., Remiao, F., Carvalho, F., Schon, M. R., Krebsfaenger, N., Doehmer, J., Bastos Mde, L. and Hengstler, J. G.: Influence of CYP2D6 polymorphism on 3,4-methylenedioxymethamphetamine (õEcstasy') cytotoxicity. Pharmacogenet. Genomics, 16: 789-799 (2006).
29. Hodgson, E.: Induction and inhibition of pesticide-metabolizing enzymes: roles in synergism of pesticides and pesticide action. Toxicol. Ind. Health, 15: 6-11 (1999).
30. Murray, M.: Mechanisms of inhibitory and regulatory effects of methylenedioxyphenyl compounds on cytochrome P450-dependent drug oxidation. Curr. Drug Metab., 1: 67-84 (2000).
31. Zhou, S. F., Wang, B., Yang, L. P. and Liu, J. P.: Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2. Drug Metab. Rev., 42: 268-354 (2010).
32. Sahi, J., Black, C. B., Hamilton, G. A., Zheng, X., Jolley, S., Rose, K. A., Gilbert, D., LeCluyse, E. L. and Sinz, M. W.: Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition. Drug Metab. Dispos., 31: 439-446 (2003).
33. Robertson, P., Decory, H. H., Madan, A. and Parkinson, A.: In vitro inhibition and induction of human hepatic cytochroe P450 enzymes by modafinil. Drug Metab. Dispos., 28: 664-671 (2000).
34. Scandlyn, M. J., Stuart, E. C. and Rosengren, R. J.: Sex-specific differences in CYP450 isoforms in humans. Expert Opin. Drug Metab. Toxicol., 4: 413-424 (2008).
35. Ou-Yang, D. S., Huang, S. L., Wang, W., Xie, H. G., Xu, Z. H., Shu, Y. and Zhou, H. H.: Phenotypic polymorphism and genderrelated differences of CYP1A2 activity in a Chinese population. Br. J. Clin. Pharmacol., 49: 145-151 (2000).
36. Catteau, A., Bechtel, Y. C., Poisson, N., Bechtel, P. R. and Bonaiti-Pellie, C.: A population and family study of CYP1A2 using caffeine urinary metabolites. Eur. J. Clin. Pharmacol., 47: 423-430 (1995).
37. Begas, E., Kouvaras, E., Tsakalof, A., Papakosta, S. and Asprodini, E. K.: In vivo evaluation of CYP1A2, CYP2A6, NAT-2 and xanthine oxidase activities in a Greek population sample by the RPHPLC monitoring of caffeine metabolic ratios. Biomed. Chromatogr., 21: 190-200 (2007).
38. Landi, M. T., Sinha, R., Lang, N. P. and Kadlubar, F. F.: Human cytochrome P4501A2. IARC Sci. Publ., 148: 173-195 (1999).
39. Carrillo, J. A., Herraiz, A. G., Ramos, S. I., Gervasini, G., Vizcaino, S. and Benitez, J.: Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steadystate concentration of olanzapine. J. Clin. Psychopharmacol., 23: 119-127 (2003).